Sharif Adeniyi Folorunso

Sharif Adeniyi Folorunso

Auto-generated profile, based on publicly available information

Sharif Adeniyi Folorunso

Department of Radiology, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2023 in ecancermedicalscience
Verified
Journal Article
Open access
SFSharif Adeniyi Folorunso
Sharif Adeniyi Folorunso
OAOyindamola Olajumoke Abiodun
Oyindamola Olajumoke Abiodun
AAAbbas Adesina Abdus-Salam
Abbas Adesina Abdus-Salam
FWFunmilola Olanike Wuraola
Funmilola Olanike Wuraola
Evaluation of side effects and compliance to chemotherapy in breast cancer patients at a Nigerian tertiary hospital Sharif Adeniyi Folorunso1, Oyindamola O

26 January 2024 in ecancermedicalscience
Verified
Journal Article
Open access
SFSharif Adeniyi Folorunso
Sharif Adeniyi Folorunso
AAAbbas Adesina Abdus-Salam
Abbas Adesina Abdus-Salam
ANAtara Isiah Ntekim
Atara Isiah Ntekim
AOAfolabi Adebayo Oladeji
Afolabi Adebayo Oladeji
MJMutiu Alani Jimoh
Mutiu Alani Jimoh
AFAminat Omolara Folorunso
Aminat Omolara Folorunso
Sociodemographic and treatment-related correlates of fatigue in breast cancer survivors at an oncology clinic in Nigeria Sharif Adeniyi Folorunso1, Abbas A

1 October 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
LTLaure-Anne Marie Nicole Teuwen
Laure-Anne Marie Nicole Teuwen
JYJoanna Young
Joanna Young
SASaleh A Alessy
Saleh A Alessy
BÖBerna C. Özdemir
Berna C. Özdemir
DMDiah Martina
Diah Martina
Eva SegelovEva Segelov
Eva Segelov
PURPOSE: Multiple disparities have been recognized in the area of location, gender, and funding for leadership in oncology clinical trials. Understanding their intersectionality is crucial to be able to formulate policies and actions, to ensure research is representative of the global oncology community. Here, data from phase III trials presented at the ASCO Annual Meeting of 2022 (ASCO22) were analyzed. METHODS: The location of institution, gender of lead and senior authors, and funding source for solid tumor phase III trial abstracts presented at the ASCO22 were analyzed. World Bank analytical grouping version 2021-2022 was used to describe regions and countries as high (HIC), upper-middle (UMIC), lower-middle (LoMIC), and low-income (LIC). RESULTS: Across 239 phase III abstracts, lead and senior authors respectively represented HIC institutions in 83% and 85%, UMIC in 13% and 12%, and LoMIC in 4% and 3%. No authors worked in LICs or sub-Saharan Africa. Women accounted for 29% of lead and 23% of senior authors. This distribution persisted across regions, with women as lead authors ranging from 19% (UMIC) to 31% (HIC), and as senior authors from 7% (UMIC) to 25% (HIC). Industry funded 62% of trials, academia 17%, and others 15%; 6% lacked funding. Industry funding was highest in HIC trials (66% for lead and senior authors), followed by UMICs (55% lead, 53% senior) and LoMICs (11% lead, 0% senior). Industry-sponsored trials were proportionally equally represented among female and male senior authors (63% each). CONCLUSION: There is marked intersectionality in leadership of oncology clinical trials presented at the world's largest oncology conference.

3 July 2022 in ecancermedicalscience
Verified
Journal Article
Open access
SFSharif Adeniyi Folorunso
Sharif Adeniyi Folorunso
ANAtara Ntekim
Atara Ntekim
AAAbbas Adesina Abdus-Salam
Abbas Adesina Abdus-Salam
AOAdeniyi Olabumuyi
Adeniyi Olabumuyi
AFAminat Omolara Folorunso
Aminat Omolara Folorunso
AAAdeniyi Abidemi Adenipekun
Adeniyi Abidemi Adenipekun
Fatigue as a complicating factor in the recovery of breast cancer survivors treated at an oncology clinic in South West Nigeria: a case–control study Shari

7 January 2026 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
CWColleen E. Witty
Colleen E. Witty
JOJoy Ogunmuyiwa
Joy Ogunmuyiwa
BYBetel Yibrehu
Betel Yibrehu
SFSharif Folorunso
Sharif Folorunso
EMErica J. Mann
Erica J. Mann
WRWilliam E. Rosa
William E. Rosa

26 May 2026 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
SFSharif Folorunso
Sharif Folorunso
BYBetel Yibrehu
Betel Yibrehu
EMErica J. Mann
Erica J. Mann
CZCatherine N. Zivanov
Catherine N. Zivanov
JGJaime Gilliland
Jaime Gilliland
WRWilliam E. Rosa
William E. Rosa
Although palliative care (PC) is recognized as a component of comprehensive care throughout the life course and universal health coverage, more than 85% of